Industry News
Pharmaceutical Industry News
In line with the Trump…
In line with the Trump administration’s goal to curb the U.S.’ reliance on overseas drug manufacturing, the FDA has deployed a new program designed to take some of the headache out of setting up domestic
Only a few months after stepping…
Only a few months after stepping into the role of senior VP of marketing and patient solutions for U.S. operations at Novo Nordisk, Ulrich Otte is no longer in the position, a company spokesperson confirmed
How Ozempic Maker Novo Nordisk Lost Its Shine
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.
A federal court of appeals judge…
A federal court of appeals judge upheld a lower court's decision to dismiss a lawsuit challenging the constitutionality of the drug price negotiation program.
Pill Causes Major Weight Loss in Eli Lilly Trial’s Results
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.
CorMedix is expanding its…
CorMedix is expanding its portfolio of infectious disease products for hospitalized patients with the acquisition of another New Jersey-based commercial-stage company, Melinta Therapeutics, for $300 million.
As the Trump administration seeks…
As the Trump administration seeks to align U.S. drug prices with lower reference costs in places like Europe, Eli Lilly’s CEO has cautioned that flaws in the American healthcare system, which “isn’t built to function
65% of HCP digital interactions…
65% of HCP digital interactions lead nowhere. Learn 5 customer journey orchestration tactics to transform static pharma websites into dynamic experiences.
Four Key Facts About Trump’s New Tariffs, and a Town Hall Showdown
Plus, inside the weight-loss drug wars.
The FDA has removed a pause in the…
The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.
Aurobindo will shell out $250…
Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S. amid threats that the Trump administration plans to impose tariffs on foreign-made drugs.
Vor Bio has handed Dallan Murray a…
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor Bio’s new-look C-suite.
Garonit Pharmaceutical, an…
Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce chlorhexidine gluconate, which is primarily used as an antiseptic and surgical disinfectant.
Impulsó el derecho a una muerte digna, empezando por la suya
Tatiana Andia sabía que Colombia le permitiría acceder a una muerte médicamente asistida. El trayecto hacia el final lo hizo ante los ojos de su país.
Merck pulled off its $10 billion…
Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically accompanies a big-money acquisition in the biopharma industry.
With more than $1 billion in debt…
With more than $1 billion in debt due in 2027, Sarepta said it’s “evaluating opportunities to enhance operational efficiency and adjust manufacturing commitments based on latest demand.”
Klick Media’s President shares…
Klick Media’s President shares his perspective on how AI is redefining planning, analytics and micro-segmentation in HCP marketing
Werewolf Therapeutics is…
Werewolf Therapeutics is transforming its brand awareness and clinical trial recruitment efforts with a new campaign.
The FDA approved Jazz’s Modeyso…
The FDA approved Jazz's Modeyso (dordaviprone), which was picked up in the company's $935 million buyout of Chimerix earlier this year, as the first systemic therapy for a rare type of brain cancer.
Pfizer CentreOne—the pharma…
Pfizer CentreOne—the pharma giant's integrated CMO outfit—is leveraging lessons learned from the COVID pandemic as it works to redefine the nature of the developer-manufacturer relationship.